Urothelial carcinoma (bladder + upper tract) · line 2 · Enfortumab vedotin monotherapy (urothelial carcinoma)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-EV-MONO-UROTHELIAL |
| ID | IND-UROTHELIAL-2L-EV |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-04 | pending_clinical_signoff |
| Diseases | DIS-UROTHELIAL |
| Sources | SRC-EV301-POWLES-2021 |
Used By
Algorithms
ALGO-UROTHELIAL-METASTATIC-2L- ALGO-UROTHELIAL-METASTATIC-2L